Office-Based Buprenorphine Treatment of Opioid Use Disorder (Online)-Module 1: Additional Resource (Slide Handout)

Module 1: Additional Resource (Slide Handout)

Pdf Summary

This document provides an overview of opioid addiction and the treatment options available, with a focus on buprenorphine. The goal of the course is to provide specific information on the pharmacology and clinical use of medication-assisted treatments for opioid use disorder, specifically buprenorphine. The program covers several topics, including the overview of opioid use disorder and the Drug Addiction Treatment Act of 2000, general opioid pharmacology, patient assessment and selection, efficacy and safety of buprenorphine, clinical use of buprenorphine, confidentiality and office policies, clinical management, evidence-based counseling, and pain patients and other special populations.<br /><br />The document also presents a case study of a 25-year-old construction worker named John who developed opioid use disorder after being prescribed oxycodone for an injury. After experiencing withdrawal symptoms and turning to heroin, John was referred to an addiction specialist and is seeking the most effective treatment option for him.<br /><br />The content also discusses the importance of confirming the diagnosis of opioid use disorder, assessing the patient's motivation and ability to engage in medication-assisted treatment (MAT), and educating the patient on the advantages and limitations of each medication option.<br /><br />Furthermore, the document highlights the treatment goals for opioid use disorder, which include reducing or ceasing opioid use, protecting against the risk of overdose and death, and improving physical and psychological health. It emphasizes the need for a combination of medication-assisted treatment, psychosocial/behavioral approaches, self-help/mutual support groups, and recovery-oriented activities.<br /><br />The legislative changes in the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016 are also discussed, as well as the practitioner requirements and regulations for office-based treatment of opioid use disorder using buprenorphine. The document emphasizes the importance of complying with these regulations and provides additional resources for practitioners to support medication-assisted treatment. Finally, the document mentions the evaluation period for the legislation and the potential for future revisions or changes based on the outcomes of these evaluations.

Keywords

opioid addiction

buprenorphine

medication-assisted treatment

opioid use disorder

pharmacology

patient assessment

clinical use

treatment goals

legislative changes

regulations